FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080334544> ?p ?o ?g. }

• W2080334544 endingPage "356" @default.
• W2080334544 startingPage "356" @default.
• W2080334544 abstract "We evaluated the tolerability and cardiac safety of docetaxel, cyclophosphamide, and trastuzumab (TCyH) for the treatment of early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared to the standard trastuzumab-based chemotherapy regimens doxorubicin with cyclophosphamide followed by paclitaxel and trastuzumab (AC-TH) and docetaxel, carboplatin, and trastuzumab (TCaH).We retrospectively reviewed early-stage, resectable, HER2-positive breast cancer patients treated with trastuzumab-based chemotherapy at a single comprehensive cancer center between 2004 and 2011. Patient characteristics, comorbidities, relative dose intensity (RDI) of each regimen, tolerability, and cardiac toxicity were evaluated.One hundred seventy-seven patients were included in the study (AC-TH, n=114; TCaH, n=39; TCyH, n=24). TCyH was solely administered in the adjuvant setting, whereas two-thirds of the AC-TH and TCaH groups were administered postoperatively. Patients treated with TCyH tended to have a more significant underlying cardiac history, higher Charlson comorbidity index, and were of an earlier stage. All patients treated with TCyH received granulocyte colony stimulating factor primary prophylaxis. No febrile neutropenia or grade ≥3 hematologic toxicity was observed in the TCyH group as compared to the AC-TH and TCaH groups. There were no significant differences in the rates of early termination, hospitalization, dose reduction, or RDI between the regimens. The symptomatic congestive heart failure rate between AC-TH, TCaH, and TCyH groups was not significantly different (4.4% vs. 2.6% vs. 8.3%, respectively, p=0.57). There was also no significant difference in the rate of early trastuzumab termination between patients treated with each regimen.TCyH is well tolerated and should be investigated as an alternative adjuvant chemotherapy option for patients who are not candidates for standard trastuzumab-containing regimens. Larger clinical trials are necessary to support the wider use of TCyH as an adjuvant regimen." @default.
• W2080334544 created "2016-06-24" @default.
• W2080334544 creator A5031159195 @default.
• W2080334544 creator A5048446049 @default.
• W2080334544 creator A5057034431 @default.
• W2080334544 creator A5064016033 @default.
• W2080334544 creator A5064444160 @default.
• W2080334544 creator A5090359583 @default.
• W2080334544 date "2014-01-01" @default.
• W2080334544 modified "2023-10-18" @default.
• W2080334544 title "Safety and Tolerability of Docetaxel, Cyclophosphamide, and Trastuzumab Compared to Standard Trastuzumab-Based Chemotherapy Regimens for Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer" @default.
• W2080334544 cites W1899541887 @default.
• W2080334544 cites W1972716219 @default.
• W2080334544 cites W1974289641 @default.
• W2080334544 cites W1974727303 @default.
• W2080334544 cites W1975777491 @default.
• W2080334544 cites W1997661997 @default.
• W2080334544 cites W2000445173 @default.
• W2080334544 cites W2015554240 @default.
• W2080334544 cites W2024607366 @default.
• W2080334544 cites W2036450045 @default.
• W2080334544 cites W2040935952 @default.
• W2080334544 cites W2048492415 @default.
• W2080334544 cites W2069191600 @default.
• W2080334544 cites W2096884232 @default.
• W2080334544 cites W2098775844 @default.
• W2080334544 cites W2105436256 @default.
• W2080334544 cites W2106777108 @default.
• W2080334544 cites W2115432999 @default.
• W2080334544 cites W2125620887 @default.
• W2080334544 cites W2136166698 @default.
• W2080334544 cites W2141393790 @default.
• W2080334544 cites W2141546964 @default.
• W2080334544 cites W2142195688 @default.
• W2080334544 cites W2144124503 @default.
• W2080334544 cites W2146384083 @default.
• W2080334544 cites W2149876820 @default.
• W2080334544 cites W2149908785 @default.
• W2080334544 cites W2169281409 @default.
• W2080334544 cites W2318605753 @default.
• W2080334544 cites W4231687826 @default.
• W2080334544 cites W4234199101 @default.
• W2080334544 doi "https://doi.org/10.4048/jbc.2014.17.4.356" @default.
• W2080334544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4278055" @default.
• W2080334544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25548584" @default.
• W2080334544 hasPublicationYear "2014" @default.
• W2080334544 type Work @default.
• W2080334544 sameAs 2080334544 @default.
• W2080334544 citedByCount "7" @default.
• W2080334544 countsByYear W20803345442015 @default.
• W2080334544 countsByYear W20803345442016 @default.
• W2080334544 countsByYear W20803345442017 @default.
• W2080334544 countsByYear W20803345442020 @default.
• W2080334544 countsByYear W20803345442021 @default.
• W2080334544 crossrefType "journal-article" @default.
• W2080334544 hasAuthorship W2080334544A5031159195 @default.
• W2080334544 hasAuthorship W2080334544A5048446049 @default.
• W2080334544 hasAuthorship W2080334544A5057034431 @default.
• W2080334544 hasAuthorship W2080334544A5064016033 @default.
• W2080334544 hasAuthorship W2080334544A5064444160 @default.
• W2080334544 hasAuthorship W2080334544A5090359583 @default.
• W2080334544 hasBestOaLocation W20803345441 @default.
• W2080334544 hasConcept C121608353 @default.
• W2080334544 hasConcept C126322002 @default.
• W2080334544 hasConcept C143998085 @default.
• W2080334544 hasConcept C197934379 @default.
• W2080334544 hasConcept C2775930923 @default.
• W2080334544 hasConcept C2776694085 @default.
• W2080334544 hasConcept C2776755627 @default.
• W2080334544 hasConcept C2777063308 @default.
• W2080334544 hasConcept C2778239845 @default.
• W2080334544 hasConcept C2778375690 @default.
• W2080334544 hasConcept C2778850193 @default.
• W2080334544 hasConcept C2779786085 @default.
• W2080334544 hasConcept C2781190966 @default.
• W2080334544 hasConcept C2781413609 @default.
• W2080334544 hasConcept C2781451048 @default.
• W2080334544 hasConcept C530470458 @default.
• W2080334544 hasConcept C71924100 @default.
• W2080334544 hasConceptScore W2080334544C121608353 @default.
• W2080334544 hasConceptScore W2080334544C126322002 @default.
• W2080334544 hasConceptScore W2080334544C143998085 @default.
• W2080334544 hasConceptScore W2080334544C197934379 @default.
• W2080334544 hasConceptScore W2080334544C2775930923 @default.
• W2080334544 hasConceptScore W2080334544C2776694085 @default.
• W2080334544 hasConceptScore W2080334544C2776755627 @default.
• W2080334544 hasConceptScore W2080334544C2777063308 @default.
• W2080334544 hasConceptScore W2080334544C2778239845 @default.
• W2080334544 hasConceptScore W2080334544C2778375690 @default.
• W2080334544 hasConceptScore W2080334544C2778850193 @default.
• W2080334544 hasConceptScore W2080334544C2779786085 @default.
• W2080334544 hasConceptScore W2080334544C2781190966 @default.
• W2080334544 hasConceptScore W2080334544C2781413609 @default.
• W2080334544 hasConceptScore W2080334544C2781451048 @default.
• W2080334544 hasConceptScore W2080334544C530470458 @default.
• W2080334544 hasConceptScore W2080334544C71924100 @default.
• W2080334544 hasIssue "4" @default.
• W2080334544 hasLocation W20803345441 @default.

• next